← Back to Clinical Trials
Recruiting NCT06880094

NCT06880094 Study of Congenital Orofacial Clefts by Implementing Optical Genome Mapping

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06880094
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Orofacial Clefts
Study Type INTERVENTIONAL
Enrollment 26 participants
Start Date 2025-02-18
Primary Completion 2027-04

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
blood withdrawal

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 26 participants in total. It began in 2025-02-18 with a primary completion date of 2027-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Orofacial clefts, the most common congenital craniofacial malformations, have a complex etiology involving an interaction between genetic and environmental factors. Chromosomal abnormalities, including structural variations, represent a major cause of human pathology. Recently, technological developments and the introduction of next-generation sequencing (NGS) technologies have revolutionized the field of medical genetics. Optical genome mapping (OGM) is an innovative, high-resolution "long read" technique that enables the identification of all classes of chromosomal variation, consisting in the direct visualization of long, labeled DNA molecules throughout the genome. This technology is gradually becoming an essential tool for studying onco-hematology and constitutional genetic pathologies The purpose of this study is to search for structural chromosomal variants (SV) or copy number variants (CNV) not identifiable either by cytogenetic methods nor by "short read" NGS "short read, in individuals with oral-facial clefts with no genetic diagnosis.

Eligibility Criteria

Inclusion Criteria: * Individuals with syndromic, complex or familial oral-facial clefts * With no established genetic diagnosis * Followed up at the Amiens-Picardie University Hospital Exclusion Criteria: * genetic diagnosis of oral-facial cleft * No health insurance affiliation * Patient under guardianship or curatorship, under safeguard of justice or deprived under public law * Pregnant, parturient or breast-feeding woman

Contact & Investigator

Central Contact

Bénédicte DEMEER, MD

✉ Demeer.Benedicte@chu-amiens.fr

📞 33+322087581

Frequently Asked Questions

Who can join the NCT06880094 clinical trial?

This trial is open to participants of all sexes, studying Orofacial Clefts. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06880094 currently recruiting?

Yes, NCT06880094 is actively recruiting participants. Contact the research team at Demeer.Benedicte@chu-amiens.fr for enrollment information.

Where is the NCT06880094 trial being conducted?

This trial is being conducted at Amiens, France.

Who is sponsoring the NCT06880094 clinical trial?

NCT06880094 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 26 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology